NIDDM-Atherosclerosis Study (NIDDM-Athero)

The NIDDM-Atherosclerosis Study, funded by NHLBI, was designed as a family study to examine the genetic basis of subclinical atherosclerosis and diabetes in Hispanic families. Family members of probands with T2D were recruited in the Los Angeles area. The baseline examination of the cohort included the euglycemic hyperinsulinemic clamp test from which the two key phenotypes were obtained: insulin sensitivity (M) and metabolic clearance rate of insulin (MCRI). Genome-wide genotyping was obtained under separate funding by NIDDK as a part of the GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium.]]>
Inclusion Probands: age 50-75; NIDDM by WHO criteria of at least 5 years duration. Probands were divided into two groups based on the presence or absence of CAD and atherosclerosis. CAD+ probands had one of the following: documented myocardial infarction, catheterization proven CAD, ischemic changes on EKG, or ischemia on stress testing. CAD- probands were free of anginal symptoms, had no history of CAD, myocardial infarction, stroke or peripheral large vessel disease, had no ischemic changes on EKG, and no evidence of vascular disease on physical exam (decreased pulses, carotid bruits, etc.). Probands needed to have a spouse and at least two adult offspring willing and able to participate in the study and to be able to give informed consent. Spouses and Offspring: age 18 - 75, able to give informed consent. Exclusion Probands and spouses only had baseline bloods drawn, including for DNA and cell lines. Offspring, who underwent extensive phenotypic testing, were excluded in the following situations: Myocardial infarction, stroke, or cardiac revascularization/angioplasty within 6 months; blood pressure >200/115 mmHg; symptoms or exam evidence of congestive heart failure or known left ventricular ejection fraction <35%; pregnancy; significant medical illness; serum potassium <3.5 or >5.5 mEq/l off medications; serum albumin <2.5 g/dl; serum creatinine >2.0 mg/dl; serum AST or ALT >3x normal; hematocrit <33%.]]>
The NIDDM Athero Study was established in 1996 by the National Heart, Lung and Blood Institute (NHLBI). The NIDDM Athero Study cohort of 447 participants (representing 127 Hispanic families) was initially recruited in 1996-YEAR 2001 from the University of Southern California and City of Hope National Medical Center.]]>